News
APRE
--
0.00%
--
Insider Sell: Aprea Therapeutics
MT Newswires · 09/22 17:30
Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO
Aprea Therapeutics Inc (NASDAQ: APRE) presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase 1/2 trial in advanced solid tumors.  The trial is evaluating the safety and efficacy of eprenetapopt in combination with p...
Benzinga · 09/21 12:39
Aprea Therapeutics Presents Data From Phase 1/2 Trial Of Eprenetapopt In Advanced Solid Tumors At ESMO Congress 2021
Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today presented data
Benzinga · 09/20 20:18
Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Congress 2021
BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today presented da...
GlobeNewswire · 09/20 20:15
Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock?
Zacks.com · 09/20 12:42
SDC, EDSA and APRE among pre market gainers
ZIVO Bioscience (NASDAQ:ZIVO) +175%. Verastem (NASDAQ:VSTM) +22% Oncology's VS-6766 + defactinib combo shows promising action in ovarian cancer study Edesa Biotech (NASDAQ:EDSA) +33% announces positive phase 2 data of its monoclonal antibody in
Seekingalpha · 09/20 12:22
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 09/20 12:13
24 Stocks Moving in Monday's Pre-Market Session
Gainers Verastem, Inc. (NASDAQ: VSTM) rose 30.8% to $3.61 in pre-market trading after the company announced a mini oral presentation highlighting updated data from the ongoing investigator-sponsored Phase 1/2 FRAME study.
Benzinga · 09/20 11:00
Top Premarket Gainers
MT Newswires · 09/20 08:26
Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021
Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced an upcoming presentation of data for epreneta...
GlobeNewswire · 09/14 12:00
Are Institutions Heavily Invested In Aprea Therapeutics, Inc.'s (NASDAQ:APRE) Shares?
Every investor in Aprea Therapeutics, Inc. ( NASDAQ:APRE ) should be aware of the most powerful shareholder groups...
Simply Wall St. · 09/03 11:21
5AM Venture Management, LLC Buys Vor Biopharma Inc, Impel NeuroPharma Inc, Janux Therapeutics ...
GuruFocus News · 08/23 07:26
JP Morgan Downgrades Aprea Therapeutics to Underweight
JP Morgan analyst Jessica Fye downgrades Aprea Therapeutics (NASDAQ:APRE) from Neutral to Underweight.
Benzinga · 08/20 09:15
--JPMorgan Downgrades Aprea Therapeutics to Underweight From Neutral
MT Newswires · 08/20 06:05
ALC, MVST and PMCB among pre market gainers
Virpax Pharmaceuticals (NASDAQ:VRPX) +83%. PharmaCyte Biotech (NASDAQ:PMCB) +67%. BrainsWay Ltd BWAY +17% after FDA's Deep TMS system 510k clearance Novo Integrated Sciences (NASDAQ:NVOS) +14% subsidiary, acenzia, signs exclusive licensing agreement with p...
Seekingalpha · 08/18 12:36
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2021
Upgrades
Benzinga · 08/16 14:33
Berenberg Downgrades Aprea Therapeutics to Hold
Berenberg analyst Esther Hong downgrades Aprea Therapeutics (NASDAQ:APRE) from Buy to Hold.
Benzinga · 08/16 11:31
HC Wainwright & Co. Maintains Neutral on Aprea Therapeutics, Lowers Price Target to $4
HC Wainwright & Co. analyst Andrew Fein maintains Aprea Therapeutics (NASDAQ:APRE) with a Neutral and lowers the price target from $6 to $4.
Benzinga · 08/16 10:36
--HC Wainwright Adjusts Aprea Therapeutics' Price Target to $4 from $6, Keeps Neutral Rating
MT Newswires · 08/16 09:49
Webull provides a variety of real-time APRE stock news. You can receive the latest news about Aprea Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The Company's lead product, eprenetapopt (APR-246), is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator that is being developed in an oral dosage form.